Compile Data Set for Download or QSAR
Report error Found 447 Enz. Inhib. hit(s) with all data for entry = 12207
TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686719(US20240246937, Example 164)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611544(CHEMBL5275112 | US20240246937, Example 56)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686706(US20240246937, Example 151)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686609(US20240246937, Example 55)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611547(CHEMBL5266457 | US20240246937, Example 145)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686621(US20240246937, Example 67)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686712(US20240246937, Example 157)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686714(US20240246937, Example 159)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611549(CHEMBL5273782 | US20240246937, Example 358B)
Affinity DataEC50:  1nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686976(US20240246937, Example 419)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611545(CHEMBL5286613 | US20240246937, Example 72)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611549(CHEMBL5273782 | US20240246937, Example 358B)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686683(US20240246937, Example 128)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611552(CHEMBL5281686 | US20240246937, Example 417)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM50611543(CHEMBL5267902 | US20240246937, Example 48)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686660(US20240246937, Example 105)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686594(US20240246937, Example 41 | US20240246937, Example...)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686608(US20240246937, Example 54)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686703(US20240246937, Example 148)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686699(US20240246937, Example 144)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686702(US20240246937, Example 147)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686711(US20240246937, Example 156)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686707(US20240246937, Example 152)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686710(US20240246937, Example 155)
Affinity DataEC50:  2nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686623(US20240246937, Example 69)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686593(US20240246937, Example 39)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686589(US20240246937, Example 35)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686631(US20240246937, Example 77)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686601(US20240246937, Example 47)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686697(US20240246937, Example 142)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686597(US20240246937, Example 43)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686704(US20240246937, Example 149)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686705(US20240246937, Example 150)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686603(US20240246937, Example 49)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686701(US20240246937, Example 146)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686680(US20240246937, Example 125)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686682(US20240246937, Example 127)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686617(US20240246937, Example 63)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686681(US20240246937, Example 126)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686708(US20240246937, Example 153)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686611(US20240246937, Example 57)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686675(US20240246937, Example 120)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686709(US20240246937, Example 154)
Affinity DataEC50:  3nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686624(US20240246937, Example 70)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686847(US20240246937, Example 291)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686594(US20240246937, Example 41 | US20240246937, Example...)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686619(US20240246937, Example 65)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686717(US20240246937, Example 162)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686659(US20240246937, Example 104)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetInterleukin-1 receptor antagonist protein(Human)
Merck Sharp & Dohme

US Patent
LigandPNGBDBM686630(US20240246937, Example 76)
Affinity DataEC50:  4nMAssay Description:Using this assay, the potency (EC50) of each compound was determined from a ten-point (1:3 serial dilution) titration curve using the following outli...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

Displayed 1 to 50 (of 447 total ) | Next | Last >>
Jump to: